Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSC Oxygenation Study in Healthy Volunteers
NCT04808622Phase 1Completed
- Sponsor
- Diffusion Pharmaceuticals Inc.
- Start
- Mar 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trans sodium crocetinate in glioblastoma (GBM) and hypoxia (6 arms), sponsored by Diffusion Pharmaceuticals Inc. Primary endpoint: Dose-Response of TSC on Transcutaneous Oximetry Measurements. Started Mar 2021; status: completed.
02
Drugs
trans sodium crocetinate
03
Conditions
glioblastoma (GBM)hypoxia
Beyond the preview
Go deeper on NCT04808622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808622.